Top Page
Smith & Nephew Snats
(NYSE:SNN)
Smith & Nephew Snats (SNN) vs. SPDR S&P 500 ETF (SPY)
Smith & Nephew Snats Business Overview & Revenue Model
Smith & Nephew Snats Key Performance Indicators (KPIs)
Analyzes revenue contributions from different business units, indicating which segments are leading growth and how diversified the company's income streams are.
Main Street DataSmith & Nephew Snats Earnings Call Summary
Smith & Nephew Snats Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.97B | 5.81B | 5.55B | 5.21B | 5.21B | 4.56B |
| Gross Profit | 4.18B | 4.05B | 3.82B | 3.67B | 3.67B | 3.16B |
| EBITDA | 1.44B | 1.24B | 956.00M | 874.00M | 1.24B | 866.00M |
| Net Income | 493.64M | 412.00M | 263.00M | 223.00M | 524.00M | 448.00M |
Balance Sheet | ||||||
| Total Assets | 10.68B | 10.35B | 9.99B | 9.97B | 10.92B | 11.01B |
| Cash, Cash Equivalents and Short-Term Investments | 675.41M | 619.00M | 302.00M | 350.00M | 1.29B | 1.76B |
| Total Debt | 3.45B | 3.32B | 3.08B | 2.87B | 3.34B | 3.69B |
| Total Liabilities | 5.15B | 5.09B | 4.77B | 4.71B | 5.35B | 5.73B |
| Stockholders Equity | 5.53B | 5.26B | 5.22B | 5.26B | 5.57B | 5.28B |
Cash Flow | ||||||
| Free Cash Flow | 799.32M | 606.00M | 181.00M | 110.00M | 469.00M | 492.00M |
| Operating Cash Flow | 1.15B | 987.00M | 608.00M | 468.00M | 877.00M | 935.00M |
| Investing Cash Flow | -345.22M | -569.00M | -448.00M | -472.00M | -691.00M | -606.00M |
| Financing Cash Flow | -676.96M | -86.00M | -200.00M | -926.00M | -645.00M | 1.16B |
Smith & Nephew Snats Technical Analysis
Smith & Nephew Snats Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $11.33B | 27.91 | 10.01% | ― | 11.75% | 364.73% | |
77 Outperform | $25.89B | 37.55 | 10.14% | 0.99% | 5.15% | 60.30% | |
77 Outperform | $22.50B | 92.80 | 19.68% | ― | 27.12% | -41.72% | |
69 Neutral | $14.14B | 29.39 | 9.20% | 2.25% | 5.78% | 61.52% | |
65 Neutral | $17.54B | 21.90 | 6.41% | 1.08% | 5.47% | -23.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $26.68B | ― | ― | 3.15% | -0.76% | -55.03% |
Smith & Nephew Snats Corporate Events
Smith+Nephew has announced the appointment of Thérèse Esperdy as an independent Non-Executive Director and Senior Independent Director designate, effective December 1, 2025. Esperdy, who brings extensive experience from her roles in financial services and as a board member of international businesses, will succeed Angie Risley following the company’s AGM in May 2026. This strategic appointment is expected to enhance the company’s governance and strengthen its board with Esperdy’s expertise, particularly in highly regulated industries.
Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with total revenue reaching $1,501 million. The company highlighted strong performance in its orthopaedics, sports medicine, and advanced wound management divisions, driven by new product launches and strategic initiatives. The company maintained its full-year revenue and profit margin outlook while raising its free cash flow guidance to $750 million, reflecting improved operational efficiency. A $500 million share buyback was completed, showcasing robust cash generation. Smith & Nephew’s strategic focus on innovation and product launches continues to bolster its market position and drive growth.
Smith & Nephew reported a 5.0% underlying revenue growth in the third quarter of 2025, with a total revenue of $1,501 million, driven by strong performance in orthopaedics, sports medicine, and advanced wound management. The company has completed a $500 million share buyback and raised its free cash flow guidance to $750 million, reflecting robust cash generation and operational efficiency. New product launches, such as the CORIOGRAPH Pre-Op Planning and Modeling Services and the CENTRIO PRP System, have contributed significantly to revenue growth, supporting the company’s strategic goals and enhancing its market position.
On October 31, 2025, Smith & Nephew plc reported its total issued share capital, comprising 877,724,845 ordinary shares, with 29,017,524 held in treasury. This results in 848,707,321 shares with voting rights, a crucial figure for shareholders under the FCA’s Disclosure Guidance and Transparency Rules. This announcement ensures transparency and aids stakeholders in understanding their voting power and obligations.
On October 22, 2025, BlackRock, Inc. crossed a significant threshold in its voting rights in Smith & Nephew, reaching a total of 7.18%. This change in holdings, notified on October 23, 2025, reflects a slight increase from their previous position and could impact Smith & Nephew’s shareholder dynamics and influence within the company.
Smith & Nephew plc, a global medical technology company, announced that an interim dividend of 15.0 US cents per ordinary share will be paid on November 7, 2025. Shareholders in the UK or those who opted for sterling dividends will receive 11.26 pence per share. This announcement, initially made on August 5, 2025, reflects the company’s ongoing commitment to returning value to its shareholders.
On October 16, 2025, Smith & Nephew plc released its six-monthly block listing return, detailing the status of various share schemes from February 1 to July 31, 2025. The report highlights that the Global Share Plan 2010 saw 206 securities issued, leaving 3,756 unallotted, while the Global Share Plan 2020 issued 5,758 securities, with 403,258 remaining unallotted. Other schemes, such as the Smith & Nephew ShareSave Plan and International ShareSave Plan, reported no new issuances, maintaining their previous balances. This update provides stakeholders with insights into the company’s equity distribution and potential future financial strategies.
On October 13, 2025, BlackRock, Inc., a major shareholder, adjusted its voting rights in Smith & Nephew plc, resulting in a new total of 7.17% of voting rights. This change, notified on October 14, 2025, reflects a slight increase from the previous total of 6.76%, indicating a strategic adjustment in BlackRock’s investment in the company. The adjustment in voting rights could influence Smith & Nephew’s governance and strategic decisions, impacting its market positioning and stakeholder interests.
Smith+Nephew announced it will host Capital Markets Days in London and New York on December 8 and 11, 2025, respectively. These events will introduce the company’s new strategy following its 12-Point Plan and provide insights into its innovative portfolio aimed at driving future growth. Led by CEO Deepak Nath, these sessions are significant for institutional investors and analysts, offering a detailed view of the company’s strategic direction and growth potential.
Smith & Nephew plc, a company listed on the London Stock Exchange, announced its total issued share capital as of September 30, 2025. The company reported that it has 877,724,845 ordinary shares, with 24,102,908 held in treasury, resulting in 853,621,937 shares with voting rights. This information is crucial for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
Smith+Nephew announced that its Chief Financial Officer, John Rogers, will relocate to the United States effective September 29, 2025, to enhance leadership and oversight in the region, which contributes significantly to the company’s revenue. This move aligns with the company’s strategy to focus on the US market, allowing closer collaboration with senior leaders and supporting the execution of business strategies. Rogers’ remuneration will be adjusted to align with US market practices, with changes to his base salary, pension cash allowance, and performance-related awards.
On September 8, 2025, Smith & Nephew plc reported the sale of ordinary shares by Alison Parkes, the Chief Compliance Officer, on the London Stock Exchange. This transaction, disclosed in accordance with the UK Market Abuse Regulation, highlights the company’s commitment to transparency in its financial dealings, potentially impacting investor perceptions and market positioning.
On September 9, 2025, Smith & Nephew announced a transaction involving the sale of ordinary shares by Vasant Padmanabhan, President of Research & Development ENT, who is classified as a Person Discharging Managerial Responsibilities (PDMR). The transaction, conducted outside the trading venue, involved the sale of 17,643 shares at a price of £14.25 each. This announcement is made in compliance with the UK Market Abuse Regulation, highlighting the company’s commitment to transparency in its financial dealings.
Smith & Nephew plc, a company involved in the healthcare industry, announced on September 1, 2025, that its total issued share capital as of August 31, 2025, consists of 877,718,356 ordinary shares, with 6,748,465 held in treasury. This results in a total of 870,969,891 voting shares, which shareholders should use as a reference for notifying changes in their interest under FCA rules.
On August 27, 2025, Smith & Nephew plc announced the granting of performance and restricted share awards to Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, under the Global Share Plan 2020 and Restricted Share Plan 2024. These awards, which are based on the company’s share price on the London Stock Exchange, are part of the company’s incentive strategy to align managerial interests with shareholder value and ensure long-term commitment from key personnel.
On August 28, 2025, Smith+Nephew announced the appointment of Dr. Garheng Kong as an independent Non-Executive Director and member of the Audit Committee, effective September 1, 2025. Dr. Kong brings extensive experience in the medtech and biopharma sectors, having held various executive and non-executive roles, which is expected to enhance the company’s strategic direction and innovation capabilities.
On August 22, 2025, Smith & Nephew plc executed a share purchase transaction as part of its remuneration policy to compensate Non-Executive Directors with shares instead of cash for part of their annual fees. This move, disclosed on August 26, 2025, aligns with the UK Market Abuse Regulation and reflects the company’s strategic approach to align director interests with shareholder value, potentially impacting its governance and stakeholder relations.
On August 20, 2025, Sybella Stanley, a Non-Executive Director at Smith & Nephew plc, purchased 1,520 ordinary shares of the company on the London Stock Exchange. This transaction was part of the company’s policy to compensate its non-executive directors partially in shares, reflecting a strategic alignment of management interests with shareholder value.
On August 18, 2025, Smith & Nephew plc announced the partial vesting of awards under its Restricted Share Plan 2024, with some shares sold to cover tax obligations. Additionally, David King, a Non-Executive Director, purchased American Depository Receipts on the New York Stock Exchange, reflecting confidence in the company’s market position.
On August 12, 2025, Smith & Nephew plc announced the partial vesting of share awards under its Global Share Plan 2020. These awards, initially granted on August 11, 2023, will vest in equal tranches over three years. The recent vesting led to some shares being sold to cover tax obligations, impacting the company’s share distribution and potentially influencing stakeholder perceptions of executive compensation strategies.
On August 1, 2025, BlackRock, Inc. adjusted its holdings in Smith & Nephew PLC, a UK-based company, by acquiring or disposing of voting rights. The change resulted in BlackRock holding 6.61% of the voting rights, down from a previous 6.83%. This adjustment in holdings could influence Smith & Nephew’s shareholder dynamics and potentially impact its strategic decisions.
On August 5, 2025, Smith & Nephew plc experienced a change in its voting rights structure due to an acquisition or disposal by BlackRock, Inc. The transaction resulted in BlackRock holding 6.76% of the total voting rights, up from a previous 6.61%. This adjustment in holdings could influence Smith & Nephew’s shareholder dynamics and potentially impact its strategic decisions moving forward.
On August 6, 2025, Elga Lohler, Chief HR Officer of Smith & Nephew plc, sold ordinary shares of the company on the London Stock Exchange. This transaction was publicly disclosed in compliance with the UK Market Abuse Regulation, highlighting transparency in managerial dealings which could impact stakeholder trust and market perception.